Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Jennifer R. Brown et al.|New England Journal of Medicine|2014Cited by 1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, Alessandra Tedeschi et al.|New England Journal of Medicine|2015Cited by 1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer A. Woyach, James P. Dean et al.|American Journal of Hematology|2019Cited by 472
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|New England Journal of Medicine|2022Cited by 453